Sibutramine in cardiovascular disease: Is SCOUT the new STORM on the horizon?

European Heart Journal

Volumn 28, Issue 23, 2007, Pages 2830-2831

  Von Haehling, Stephan ^a,b   Lainscak, Mitja ^a,c   Anker, Stefan D ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; RAMIPRIL; SIBUTRAMINE; TRANDOLAPRIL PLUS VERAPAMIL;

BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; EDITORIAL; GLUCOSE TOLERANCE; HEART FAILURE; HEART RATE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PULSE RATE; SIDE EFFECT; STROKE; TACHYCARDIA; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION;

APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; DOUBLE-BLIND METHOD; HUMANS; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; WEIGHT LOSS;

EID: 36849017966     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm493     Document Type: Editorial

References (11)

1. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003.
2. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en (accessed 15 June 2007)
3. http://www.nonstopenglish.com/Reading/quotations/k_Obesity.asp (accessed 15 June 2007)
4. von Haehling S, Doehner W, Anker SD. Obesity and the heart: a weighty issue. J Am Coll Cardiol 2006;47:2274-2276.
5. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, Clark AL, Anker SD. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Cardiac Fail 2003;9:29-35.
6. Padwal RS, Majumdar SR. Drug treatment for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-77.
7. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K for the S.A.T. Study Group. Weight reduction by sibutramine in obese subjects in primary care medicine: the S.A.T Study. Exp Clin Endocrinol Diabetes 2004;112:201-207.
8. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WHM, Van Gaal LF for the STORM Study Group. Effects of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000;356:2119-2125.
9. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P, on behalf of the SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28:2915-2923. First Published on June 26, 2007, doi: 10.1093/eurheartj/ehm217.
10. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007;115:1991-1998.
11. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol 2006;106:319-322.